Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.0% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR-based gene editing therapies. Today, NTLA experienced a strong bearish movement in the market.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.0% on Jun 23, 2026 15:21

• Despite the positive Phase 3 trial data for lonvo-z targeting hereditary angioedema and the FDA filing, NTLA stock saw a bearish movement, possibly due to profit-taking by investors after a recent surge in stock price.
• The concerns raised about competition, CRISPR safety, pricing pushback, and the need for additional capital may have contributed to the bearish sentiment surrounding NTLA today.
• The stock being considered undervalued by some analysts despite the recent positive developments could indicate a disconnect between perceived value and market sentiment, leading to the bearish movement.
• The strong efficacy of lonvo-z in reducing disease episodes and the potential to challenge competitors like Ionis Pharmaceuticals may be overshadowed by broader market factors influencing NTLA's stock performance today.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing

Intellia Therapeutics (NTLA) shares surged 29.4% following positive Phase 3 HAELO trial data for its CRISPR therapy, lonvo-z, targeting hereditary angioedema. The company also filed a rolling biologics license application with the FDA and published results in the New England Journal of Medicine, positioning lonvo-z as a potential one-time treatment. Despite the strong clinical data, risks remain regarding competition, long-term CRISPR safety concerns, payer pushback on pricing, and the need for further capital raising.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-294-after-new-phase-3-lonvo

Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data

Intellia Therapeutics (NTLA) is drawing attention after releasing positive Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema and submitting a rolling biologics license application to the FDA. Despite a recent 70.14% year-to-date share price increase, the stock is considered by some narratives to be 41.2% undervalued compared to an estimated fair value of $26.63, though its high P/S ratio indicates strong market optimism. Investors are encouraged to review the company's financials and risks to form their own stance regarding its future potential.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-stock-could-be-412-undervalued-af/amp

Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price

Intellia Therapeutics (NTLA) saw a significant stock price surge of 10.7% on June 17, 2026, driven by increased investor confidence in its CRISPR/Cas9 gene-editing technology. Despite a solid GF Score™ of 72, indicating strong growth prospects, the company's low profitability rank and a trend of insider selling transactions warrant careful consideration from investors.

https://www.gurufocus.com/news/8920894/intellia-therapeutics-ntla-sees-107-surge-in-stock-price?mobile=true

NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads

Intellia Therapeutics Inc. (NTLA) stock surged by 10.24% following promising Phase 3 CRISPR gene-editing trial results for its drug lonvo-z, aimed at hereditary angioedema. The data, published in the New England Journal of Medicine and presented at EAACI 2026, showed significant attack reductions and quality-of-life improvements. Intellia is pursuing a rolling Biologics License Application with the FDA, targeting a U.S. launch in the first half of 2027, making NTLA a significant focus for traders despite its development-stage financials.

https://stockstotrade.com/news/intellia-therapeutics-inc-ntla-news-2026_06_17/

Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema

Intellia Therapeutics' CRISPR-based gene editing therapy, lonvo-z, showed significant efficacy in a Phase 3 study for hereditary angioedema, reducing disease attack episodes by 89% and moderate/severe attacks by 91%. Analysts predict lonvo-z could challenge Ionis Pharmaceuticals' angioedema drug, Dawnzera, due to its "paradigm-shifting" one-time dosing profile. Intellia expects to complete its FDA submission in the second half of this year, with potential approval and launch in the first half of 2027.

https://www.biospace.com/drug-development/intellias-gene-editor-keeps-pace-with-ionis-in-hereditary-angioedema

Trending Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Up 5.2% Today

Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.1% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.1% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.6% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 6.7% Today

Ambarella Inc. ($AMBA) Stock Forecast: Down 5.5% Today

PulteGroup Inc. ($PHM) Stock Forecast: Up 7.9% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 6.2% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 6.9% Today

Intellia Therapeutics, Inc. Price History

05.05.2026 - NTLA Stock was down 6.9%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after the significant surge in stock price following positive Phase 3 trial results and extended cash runway.
• Despite the positive sentiment surrounding the Phase 3 trial results and analyst ratings, the mixed signals on the company's valuation, with some suggesting it is already priced for future growth, might have caused caution among investors.
• The anticipation around the upcoming Phase 3 HAELO trial data release for lonvo-z therapy could have led to heightened volatility and uncertainty in the stock price, prompting some investors to take a step back and reassess their positions.
• The discrepancy between the perceived undervaluation by some analysts and the high price relative to peers based on market multiples may have created a sense of ambiguity among investors, contributing to the bearish movement in NTLA stock today.

23.05.2026 - NTLA Stock was down 5.0%

• Despite the positive Phase 3 trial data for lonvo-z targeting hereditary angioedema and the FDA filing, NTLA stock saw a bearish movement, possibly due to profit-taking by investors after a recent surge in stock price.
• The concerns raised about competition, CRISPR safety, pricing pushback, and the need for additional capital may have contributed to the bearish sentiment surrounding NTLA today.
• The stock being considered undervalued by some analysts despite the recent positive developments could indicate a disconnect between perceived value and market sentiment, leading to the bearish movement.
• The strong efficacy of lonvo-z in reducing disease episodes and the potential to challenge competitors like Ionis Pharmaceuticals may be overshadowed by broader market factors influencing NTLA's stock performance today.

05.05.2026 - NTLA Stock was down 9.7%

• Expectations and optimism preceding the Phase 3 results of the lonvo-z study for hereditary angioedema (HAE) likely drove a significant price surge before the announcement.
• Despite initial positivity and strong performance in gene-editing technology, the market response to the actual Phase 3 results may have been negative, potentially falling below expectations.
• Conflicting viewpoints on the company's valuation, with some suggesting it is undervalued while market comparisons suggest a higher price compared to industry peers, could have prompted profit-taking and the bearish movement in the stock price.
• Investors may be reassessing their positions and weighing the potential risks and rewards linked to Intellia Therapeutics, resulting in a sell-off and the bearish movement witnessed today.

18.05.2026 - NTLA Stock was down 5.6%

• NTLA's stock saw a notable downturn despite the release of favorable additional Phase III data from their HAE gene-editing therapy study.
• The market response could be linked to investors taking profits following a recent stock price surge driven by encouraging Phase 3 trial outcomes and heightened investor confidence in the company's technology.
• Despite these positive updates, concerns about the company's low profitability rank and insider selling activities might have influenced the downward trend.
• Analysts predominantly recommend buying NTLA shares, but this might not have been sufficient to counterbalance profit-taking and investor apprehension, resulting in the bearish market movement.

09.05.2026 - NTLA Stock was down 6.9%

• Intellia Therapeutics (NTLA) stock witnessed a notable decline in value recently.
• The fluctuation in the market may be linked to varying opinions among analysts concerning the company's growth outlook, despite positive results from the Phase 3 trial of its HAE treatment, lonvoguran ziclumeran.
• Investors seemed apprehensive about the perceived risk associated with the lonvo-z therapy, potentially influenced by recent developments.
• Furthermore, a surge in stock value driven by optimistic expectations for the forthcoming Phase 3 data might have prompted traders to capitalize on profits, contributing to the downward trajectory in the stock's price.

16.05.2026 - NTLA Stock was up 7.7%

• The notable increase in Intellia Therapeutics' stock price is attributed to the impressive Phase 3 results of its Lonvo-Z treatment, which demonstrated an 87% reduction in monthly attacks compared to placebo alongside favorable safety outcomes.
• The upsurge in options trading volume, particularly in call options, reflects heightened investor optimism and confidence in the company's future prospects post the positive clinical data.
• Despite a Sell rating on NTLA from Goldman Sachs with a target price of $9, market sentiment appears to have turned positive due to the encouraging therapeutic outcomes and the company's strategic advancements in the gene-editing field.
• The unveiling of additional Phase 3 data, revealing an 89% reduction in attacks necessitating rescue medication and enhancements in quality of life, further boosted investor enthusiasm and contributed to the stock's premarket surge, hinting at a potentially revolutionary in vivo gene-editing medicine with Lonvo-Z.

11.05.2026 - NTLA Stock was down 6.5%

• NTLA stock showed bearish movement recently.
• Concerns arose due to the substantial awarding of stock options and RSUs to various company directors, possibly raising worries about share dilution and downward pressure on stock value.
• Investors may view these equity grants as lack of faith in the company's short-term performance or anticipate upcoming challenges, prompting a sell-off of NTLA stocks.
• Market sentiment appears influenced by perceptions of leadership hedging rather than holding onto shares, potentially signaling caution to investors.

02.05.2026 - NTLA Stock was down 7.1%

• The bearish movement in NTLA's stock price today could be attributed to profit-taking by investors after a recent surge in the stock following positive Phase III trial results for its CRISPR-based therapy, lonvoguran ziclumeran.
• Despite the successful pivotal trial results for NTLA-2001 in treating ATTR amyloidosis with cardiomyopathy, the market may have reacted negatively due to concerns about the company's ongoing need for equity offerings to fund development, indicating potential dilution for existing shareholders.
• The undervaluation of NTLA highlighted by analysts, despite positive developments, might have also contributed to the bearish sentiment as investors may be cautious about the company's ability to secure strong payer support for expensive gene editing treatments in the future.
• Overall, the market movement in NTLA today reflects a mix of profit-taking, concerns about funding strategies, and uncertainties surrounding the commercialization and market acceptance of its CRISPR-based therapies.

15.05.2026 - NTLA Stock was up 5.6%

• NTLA stock surged 5% premarket after releasing additional Phase 3 data for its CRISPR-based hereditary angioedema (HAE) treatment, Lonvo-z, showing an 89% reduction in attacks requiring rescue medication and significant quality-of-life improvements.
• The positive Phase 3 results for Lonvo-z, with an 87% reduction in mean monthly HAE attacks and improvements in quality of life, have sparked investor optimism and confidence in the potential success of the drug.
• The anticipation of regulatory approval and a U.S. launch of Lonvo-z in the first half of 2027 has further fueled the bullish sentiment around NTLA stock.
• Despite a recent decline since its last earnings report, the promising developments in the Phase 3 trials have overshadowed concerns about the stock's previous performance, leading to a notable uptick in NTLA's market value.

17.05.2026 - NTLA Stock was up 14.0%

• NTLA shares surged by 23.2% after announcing positive additional data from its phase III HAELO study for lonvo-z, a gene-editing therapy for hereditary angioedema (HAE).
• The encouraging results showcased a significant reduction in monthly rates of HAE attacks, demonstrating the potential efficacy of Lonvo-Z for disease control.
• Analysts' Buy ratings and the company's plans for FDA approval and commercial launch in the first half of 2027 further fueled investor optimism, leading to the substantial increase in NTLA's stock price.
• The strong market response indicates growing confidence in Intellia Therapeutics' innovative gene-editing approach and the potential market impact of Lonvo-Z in addressing genetic diseases like HAE.

10.05.2026 - NTLA Stock was down 5.5%

• The decrease in NTLA's stock price today could be linked to a notable rise in short interest to 46.78% of the float. This surge in short interest may reflect increasing investor pessimism or concerns about the company's future prospects.
• Despite positive Phase 3 trial outcomes for its hereditary angioedema treatment, lonvoguran ziclumeran, and positive FDA developments, the stock appears to be under downward pressure due to valuation worries. Analysts believe NTLA is undervalued by 49.3% and faces potential valuation risks compared to industry peers.
• The recent equity raise by Intellia Therapeutics is also likely contributing to the current bearish sentiment, as investors may be cautious about potential dilution or the company's efficiency in utilizing the raised capital for future expansion.
• The forthcoming presentation of Phase 3 data for lonvo-z at the European Academy of Allergy & Clinical Immunology Congress 2026 could prove to be an important event for NTLA, potentially influencing investor sentiment and the stock's short-term movement.

04.05.2026 - NTLA Stock was up 18.0%

• NTLA stock surged due to the successful results of its CRISPR-based treatment, NTLA-2001, in a pivotal Phase 3 trial for ATTR amyloidosis with cardiomyopathy, demonstrating a significant reduction in mortality and cardiovascular events.
• The positive Phase III results for its CRISPR therapy, lonvoguran ziclumeran, and the FDA lifting clinical holds on another candidate, nexiguran ziclumeran, also contributed to the stock's rise.
• Analysts view NTLA as undervalued, presenting a potential buying opportunity as the company prepares to release Phase 3 HAELO trial data for lonvo-z, its gene-editing therapy for hereditary angioedema.
• The company's success in advancing its gene-editing therapies towards potential commercialization, alongside ongoing clinical achievements, has boosted investor confidence in NTLA's future prospects, driving the bullish market movement.